Cargando…

Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry

BACKGROUND: Azilsartan medoxomil (AZL-M), has been demonstrated to be more effective than the other sartans currently in use; however, there is insufficient information available comparing it with ACE-inhibitors. Therefore, we aimed to compare the efficacy, safety, and tolerability of AZL-M with tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gitt, Anselm K., Bramlage, Peter, Potthoff, Sebastian A., Baumgart, Peter, Mahfoud, Felix, Buhck, Hartmut, Ehmen, Martina, Ouarrak, Taoufik, Senges, Jochen, Schmieder, Roland E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784379/ https://www.ncbi.nlm.nih.gov/pubmed/26956148 http://dx.doi.org/10.1186/s12872-016-0222-6

Ejemplares similares

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
por: Bramlage, Peter, et al.
Publicado: (2015)

EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry
por: Gitt, Anselm K, et al.
Publicado: (2013)

Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry
por: Schmieder, Roland E, et al.
Publicado: (2015)

Individualised treatment targets in patients with type-2 diabetes and hypertension
por: Schmieder, Roland E., et al.
Publicado: (2018)

Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice – study rationale and protocol of DIALOGUE
por: Gitt, Anselm K, et al.
Publicado: (2012)

Incidence and predictors of hypoglycaemia in type 2 diabetes – an analysis of the prospective DiaRegis registry
por: Tschöpe, Diethelm, et al.
Publicado: (2012)

Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry
por: Tschöpe, Diethelm, et al.
Publicado: (2011)

Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy – an analysis of the DiaRegis registry
por: Wasem, Jürgen, et al.
Publicado: (2013)

One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry
por: Puls, Miriam, et al.
Publicado: (2016)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up
por: Bramlage, Peter, et al.
Publicado: (2014)

The management of acute venous thromboembolism in clinical practice: Results from the European PREFER in VTE Registry
por: Cohen, Alexander T., et al.
Publicado: (2017)

Azilsartan: Current Evidence and Perspectives in Management of Hypertension
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Efficacy and Safety of Azilsartan and Telmisartan in Hypertensive Patients
por: Kumar, Alok, et al.
Publicado: (2021)

Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia
por: Bramlage, Peter, et al.
Publicado: (2012)

Sex Differences in Percutaneous Coronary Intervention—Insights From the Coronary Angiography and PCI Registry of the German Society of Cardiology
por: Heer, Tobias, et al.
Publicado: (2017)

Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline
por: Bramlage, Peter, et al.
Publicado: (2010)

Critical evaluation of the efficacy and tolerability of azilsartan
por: De Caterina, Alberto R, et al.
Publicado: (2012)

Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension
por: Shuster, Jerrica E, et al.
Publicado: (2012)

Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study
por: Schmieder, Roland E, et al.
Publicado: (2012)

Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice
por: Schmieder, Roland E, et al.
Publicado: (2009)

The COVID-19 Registry in Rhineland-Palatinate in the context of international registry activities documenting COVID-19 outcomes
por: Gitt, Anselm K., et al.
Publicado: (2020)

Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
por: Gitt, Anselm K., et al.
Publicado: (2022)

Improvement of Diurnal Blood Pressure Variation by Azilsartan
por: Okamura, Keisuke, et al.
Publicado: (2018)

A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone
por: Weber, Michael A, et al.
Publicado: (2018)

The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
por: Tschöpe, Diethelm, et al.
Publicado: (2013)

Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension
por: Weber, Michael A., et al.
Publicado: (2014)

Management of the COVID-19 pandemic in Rhineland-Palatinate hospitals of all levels of care: Results of the COVID-19 Registry RLP
por: Gitt, Anselm K., et al.
Publicado: (2023)

Azilsartan/chlorthalidone combination therapy for blood pressure control
por: Cheng, Judy WM
Publicado: (2013)

Optimization, characterization and in vitro/vivo evaluation of azilsartan nanocrystals
por: Ma, Jingjing, et al.
Publicado: (2017)

New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
por: Volpe, Massimo, et al.
Publicado: (2012)

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy
por: Angeloni, Emiliano
Publicado: (2016)

Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry
por: Mahfoud, Felix, et al.
Publicado: (2019)

Differential pharmacology and benefit/risk of azilsartan compared to other sartans
por: Kurtz, Theodore W, et al.
Publicado: (2012)

Crystal structure of azilsartan methyl ester ethyl acetate hemisolvate
por: Li, Zhengyi, et al.
Publicado: (2015)

In-hospital major arrhythmias, arrhythmic death and resuscitation after successful primary percutaneous intervention for acute transmural infarction: a retrospective single-centre cohort study
por: Albanese, Marco, et al.
Publicado: (2018)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018)

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
por: Johnson, Wallace, et al.
Publicado: (2017)

Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension
por: Iwashima, Yoshio, et al.
Publicado: (2023)

Spectrophotometric and Spectrofluorimetric Studies on Azilsartan Medoxomil and Chlorthalidone to Be Utilized in Their Determination in Pharmaceuticals
por: Ebeid, Walid M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_60gtupv1hhf67e1ud3gbthg1dm